About US
Contact us
-
After price deal, Takeda's lung cancer drug Exkivity wins UK green light ahead of J&J rivalIn their running battle to treat a rare form of non-small cell lung cancer, Johnson & Johnson got the jump on Takeda in the United States last year. But now Takeda has one-upped J&J in the U.2022/3/23
-
Pfizer's deal with Medicines Patent Pool includes 35 companies from 12 countries to produce generic PaxlovidAs the coronavirus surged around the globe, Pfizer was among the vaccine makers who had to fend off criticism for protecting the technology behind its COVID-19 shots. Upon the development of its COVI2022/3/21
-
Eisai's reduced Aduhelm role; Chinese biotechs' US delisting risks; Zai Lab's new COO from LillyEisai has decided to exit its supporting role for Biogen's Alzheimer's drug Aduhelm. Chinese companies including several biotechsface potential U.S. delisting if they fail to comply with a new audit2022/3/21
-
After Alexion buyout, AstraZeneca pays Roche $775M to settle Ultomiris patent brawlAstraZeneca and Roche recently decided to end a patent infringement fight around Ultomiris. Now, we know the price of the deal. AstraZeneca’s Alexion willpay$775 million to Roche’s Chugai Pharm2022/3/18
-
Biotech execs who pinched Genentech trade secrets headed to prisonTop execs at Taiwanese biosimilars outfit JHL Biotech are headed to prison after pleading guilty last August to stealing trade secrets from Roche’s Genentech. Racho Jordanov, co-founder and for2022/3/18
-
BeiGene, Hutchmed, Zai Lab tagged for potential US delisting under SEC audit rules, with more Chinese biotechs likely to face scrutinyThe U.S. securities watchdog has set the countdown timer for the delisting of three leading Chinese biotechs from the Nasdaq as a newly installed foreign audit law threatens to banish more Chinese fi2022/3/16
-
Fierce Pharma Asia—Legend CEO's cell therapy ambitions; Indian pharmas' awkward position; new Hutchmed CEOAfter its first commercial launch in Carvykti, Legend Biotech's CEO talked up the rising CAR-T star's cell therapy ambitions. The Indian government's reluctanceto take a harsh stance on Russia could2022/3/16
-
Lonza completes lab expansion at Chinese API production plantLonza completed a laboratoryexpansion projectat its API manufacturing facility in Nansha, China. The project, which grew the footprint of the lab by 250 square meters, included the addition of2022/3/14
-
India's hesitance to condemn Russia puts the country's pharma industry in compromising positionRussia’s invasion of Ukraine has put India in a compromising position. To protect itself against China, India has courted favor with both the European Union and Russia. With those powers on opposing2022/3/14
-
Biogen starts layoff round as the Aduhelm maker struggles with Alzheimer's rolloutBiogen’s $500 million restructuring plan is starting to take a toll on its employees. The company has started sending out layoff letters to some employees in the U.S., Biogen said in a statemen2022/3/9